Cipla Primes Biosimilars Play Via South African Beachhead
Executive Summary
South Africa’s first biotech manufacturing facility is being set up by India's Cipla which hopes its strategy of "one global product standard at affordable pricing" could transform the biosimilars market. Some years ago, Cipla revolutionized treatment for HIV/AIDS with its less than a dollar a day treatment, though some analysts claim that it's still very early days to factor any disruptive impact that the firm could potentially have in the complex biosimilars segment.
You may also be interested in...
Cipla, Guojian launch first biosimilar Enbrel in India
Cipla has launched the first cut-price etanercept, a biosimilar version of Amgen's Enbrel, in India under an alliance with Shanghai CP Guojian Pharmaceutical, marking the Indian generic company's much anticipated entry into the biologics space.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet